CoChat

The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review

Open access

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Abstract

The extracellular buildup of amyloid beta (Aβ) plaques in the brain is a hallmark of Alzheimer’s disease (AD). Detection of Aβ pathology is essential for AD diagnosis and for identifying and recruiting research participants for clinical trials evaluating disease-modifying therapies. Currently, AD diagnoses are usually made by clinical assessments, although detection of AD pathology with positron emission tomography (PET) scans or cerebrospinal fluid (CSF) analysis can be used by specialty clinics. These measures of Aβ aggregation, e.g. plaques, protofibrils, and oligomers, are medically invasive and often only available at specialized medical centers or not covered by medical insurance, and PET scans are costly. Therefore, a major goal in recent years has been to identify blood-based biomarkers that can accurately detect AD pathology with cost-effective, minimally invasive procedures. To assess the performance of plasma Aβ assays in predicting amyloid burden in the central nervous system (CNS), this review compares twenty-one different manuscripts that used measurements of 42 and 40 amino acid-long Aβ (Aβ42 and Aβ40) in plasma to predict CNS amyloid status. Methodologies that quantitate Aβ42 and 40 peptides in blood via immunoassay or immunoprecipitation-mass spectrometry (IP-MS) were considered, and their ability to distinguish participants with amyloidosis compared to amyloid PET and CSF Aβ measures as reference standards was evaluated. Recent studies indicate that some IP-MS assays perform well in accurately and precisely measuring Aβ and detecting brain amyloid aggregates.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13195-022-01117-1

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Timeline of Aβ studies [7, 10–25]. Timeline denoting significant events surrounding plasma Aβ use as a biomarker in AD diagnosis, color-coded by assay type. Results were conflicting for many years, but recent IP-MS studies provide promising AUC values for plasma Aβ42/40 measures. The diagnostic reference standard used in each study is listed in parentheses. For studies that used PET as a reference, the tracers include Pittsburg Compound B [7, 17–21, 25], flutemetamol [17, 20, 22, 23], florbetapir [17, 18, 20, 22, 24], and florbetaben [20]. Abbreviations: Disc., Discovery; Val., Validation. Figure created with BioRender.com
Fig. 1 Timeline of Aβ studies [7, 10–25]. Timeline denoting significant events surrounding plasma Aβ use as a biomarker in AD diagnosis, color-coded by assay type. Results were conflicting for many years, but recent IP-MS studies provide promising AUC values for plasma Aβ42/40 measures. The diagnostic reference standard used in each study is listed in parentheses. For studies that used PET as a reference, the tracers include Pittsburg Compound B [7, 17–21, 25], flutemetamol [17, 20, 22, 23], florbetapir [17, 18, 20, 22, 24], and florbetaben [20]. Abbreviations: Disc., Discovery; Val., Validation. Figure created with BioRender.comCC BY · PubMed Central
Fig. 2 Contrasting methods to measure plasma Aβ. Two common methods to measure plasma Aβ are IP-MS assays (left) and immunoassays (right). In IP-MS assays, the detector measures Aβ species directly and quantitation is performed with an internal standard of stable isotope-labeled Aβ. In immunoassays, Aβ species are measured indirectly with antibody binding, and a different detection antibody must be used for each Aβ isoform. Immunoassays perform quantitation with an external standard. The immunoassay depicted in this figure is a plate-based sandwich immunoassay; bead-based immunoassays are also common, using fluorescently barcoded beads bound to an antibody for indirect measuring of a target. Figure created with BioRender.com
Fig. 2 Contrasting methods to measure plasma Aβ. Two common methods to measure plasma Aβ are IP-MS assays (left) and immunoassays (right). In IP-MS assays, the detector measures Aβ species directly and quantitation is performed with an internal standard of stable isotope-labeled Aβ. In immunoassays, Aβ species are measured indirectly with antibody binding, and a different detection antibody must be used for each Aβ isoform. Immunoassays perform quantitation with an external standard. The immunoassay depicted in this figure is a plate-based sandwich immunoassay; bead-based immunoassays are also common, using fluorescently barcoded beads bound to an antibody for indirect measuring of a target. Figure created with BioRender.comCC BY · PubMed Central
Fig. 3 Forest plots of all AUC values with PET and CSF references. The points are categorized and color-coded by assay type, and the horizontal bars represent a 95% confidence interval. Blue is IP-MS assay, yellow is ECL, orange is an antibody-free LC-MS assay, green is ELISA, and red is SIMOA. The black diamond symbols represent the weighted average of the assays for each category, and within categories, the assay name is listed on the y-axis. The size of each point corresponds to the sample size of the cohort and the diagnostic accuracy of AUC values is depicted on a scale below the x-axis [27]. Abbreviations: WashU, Washington University; Univ. Got., University of Gothenburg
Fig. 3 Forest plots of all AUC values with PET and CSF references. The points are categorized and color-coded by assay type, and the horizontal bars represent a 95% confidence interval. Blue is IP-MS assay, yellow is ECL, orange is an antibody-free LC-MS assay, green is ELISA, and red is SIMOA. The black diamond symbols represent the weighted average of the assays for each category, and within categories, the assay name is listed on the y-axis. The size of each point corresponds to the sample size of the cohort and the diagnostic accuracy of AUC values is depicted on a scale below the x-axis [27]. Abbreviations: WashU, Washington University; Univ. Got., University of GothenburgCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Research works printed but not linked: 2

  1. Clinical and Laboratory Standards Institute (CLSI). Quantitative measurement of proteins and peptides by mass dpectrometry. In: CLSI guideline C64 (ISBN 978-1-68440-110-9) [Print]. 1st ed. USA: Clinical and Laboratory Standards Institute; 2021.
  2. Kaneko N, Nakamura A, Yoda R, Kato T, Sekiya S, Ito K, et al. S. High concordance between plasma amyloid β biomarkers by IP-MALDI-MS and visual assessment of amyloid PET. San Diego: Poster presented at: Alzheimer’s Association International Conference; 2022.

Cited by

See all 151

Metadata

Authors
Brand, A. L., Lawler, P. E., Bollinger, J. G., Li, Y., Schindler, S. E., Li, M., Lopez, S., Ovod, V., Nakamura, A., Shaw, L. M., Zetterberg, H., Hansson, O., & Bateman, R. J.
Affiliations
  • Washington University in St. Louis (US)
  • National Center for Geriatrics and Gerontology (JP)
  • University of Pennsylvania (US)
  • Sahlgrenska University Hospital (SE)
  • Lund University (SE)
Corresponding author
Bateman, Randall J.
Venue
Alzheimer's Research & Therapy
Published
2022-12-27
Volume
14
Issue
1
Pages
195-195
ISSN
1758-9193 (ISSN-L)
OpenAlex
W4312200695
Cited by
151
References
68
Citations by year
2026: 28 · 2025: 47 · 2024: 53 · 2023: 23
FWCI
4.23
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s Research & Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • European Commission (860197)
  • Vetenskapsrådet (2016-00906)
  • National Institute on Aging (R21AG067559, RF1AG061900, U19AG024904, R01AG070941, P30AG072979)
  • National Institute of Mental Health (R01MH117114)
  • National Institute of Neurological Disorders and Stroke (R01NS095773)
  • H2020 European Research Council (681712)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
Keywords
Alzheimer's disease, amyloid-beta, plasma biomarkers, amyloid plaques, amyloid-beta 42, Aβ40, immunoprecipitation mass spectrometry, immunoassay, amyloid PET, cerebrospinal fluid amyloid, amyloidosis, blood-based diagnosis, diagnostic accuracy
MeSH terms
Alzheimer Disease, Amyloid, Brain, Humans, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, Positron-Emission Tomography, Plaque, Amyloid, Amyloidogenic Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review. https://app.cochat.ai/papers/10.1186/s13195-022-01117-1
The paper
Brand, A. L., Lawler, P. E., Bollinger, J. G., Li, Y., Schindler, S. E., Li, M., Lopez, S., Ovod, V., Nakamura, A., Shaw, L. M., Zetterberg, H., Hansson, O., & Bateman, R. J. (2022). The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-022-01117-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.